Advertisement

Advertisement

Case 3: Optimal Sequencing of T-Cell–Redirected Therapies

This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with high-risk multiple myeloma that is progressing following maintenance therapy. The patient is a 65-year-old man with back pain, anemia, and lytic bone disease with 70% bone marrow plasma cells (deletion 17p and 1q amplification) His IgA kappa is 6.5 g/dL, and kappa:lambda ratio is 800. He is treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone, achieving a measurable residual disease (MRD)-negative complete response after eight cycles. He undergoes stem cell collection, but defers autologous stem cell transplant and receives carfilzomib plus lenalidomide maintenance for 2 years. Four years later, he has increasing MRD while in complete response.

 

In the conversation that follows, the faculty discuss how increasing MRD informs treatment decisions, the clinical data supporting the use of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel, and considerations when sequencing CAR T-cell therapies and bispecific T-cell engagers.



Advertisement
Advertisement